2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC

Pdf Summary

This study focuses on the prevalence and risk factors of thromboembolic events (TEs) in patients with oncogene-addicted advanced non-small cell lung cancer (aNSCLC). Conducted as a single-center, retrospective analysis, it included patients diagnosed post-January 1, 2015, who underwent comprehensive molecular profiling (next-generation sequencing or FISH) and had at least six months of follow-up.<br /><br />The results reveal that TEs, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, are notably higher in aNSCLC patients with oncogenic fusions, rising from a general NSCLC incidence of 5-14% to 30-48% for specific genomic categories. Key findings indicate that patients with ROS1 fusions, MET exon 14 mutations, and those with metastatic disease from diagnosis face the highest risk for venous TEs. Additionally, RET fusions and advanced age (65 years or older) are significantly associated with an increased risk of ischemic strokes.<br /><br />The study's multivariable analysis determined that specific genomic alterations like ROS1 and MET correlate strongly with venous TEs, while RET mutations and older age are more predictive of ischemic stroke occurrence. ROS1, RET, and KRAS with negative genomic indicators lead to early TE incidences, whereas EGFR, BRAF V600E, and ALK alterations contribute to later occurrences.<br /><br />The data suggest that personalized treatment strategies and timelines for monitoring TEs should consider the genetic profile of aNSCLC patients, especially those with oncogenic fusions or mutations. This approach could potentially mitigate the increased morbidity, mortality, and healthcare costs associated with TEs in this patient population.

Asset Subtitle

Mihaela Aldea

Meta Tag

Speaker Mihaela Aldea

Topic Metastatic NSCLC – Targeted Therapy

Keywords

thromboembolic events

oncogene-addicted

non-small cell lung cancer

molecular profiling

genomic alterations

venous thromboembolism

ischemic stroke

personalized treatment

oncogenic fusions

retrospective analysis